SNPMiner Trials (Home Page)
Report for Mutation G719C
 Developed by Shray Alag, 2020.
SNP Clinical Trial Gene 
There are 3 clinical trials
Clinical Trials
      Preclinical data in lung cancer cell lines showed that EGFR mutation can potentially be a
      positive predictor for sensitivity to BKM120. Furthermore, when the erlotinib-resistant model
      H1975 (LR858 and T790M mutation) was treated with BKM120, significant tumor control was
      observed (Novartis internal data). Therefore, combining BKM120 with erlotinib could
      potentially down-modulate PI3K-Akt activity resulting in a synergistic effect on cell growth
      inhibition and enhancing the response to erlotinib.
    
These include, but are not limited to mutations in L858R (Exon
                  21); Exon 19 deletion; G719S, G719A, G719C mutations (Exon 19);or L861Q
                  (laboratory report required at enrollment). --- L858R ---  --- G719S ---  --- G719A ---  --- G719C --- 
  Primary Outcomes 
 Description: Percentage of patients who are alive and progression-free at 3 months (APF3) from first treatment.
 Measure: Progression Free Survival at 3 Months
 Time: 3 months
  Secondary Outcomes 
 Description: Defined as the time from first treatment until death from any cause.
 Measure: Overall Survival
 Time: every 3 months after study treatment, projected 24 months
 Description: Defined as the time from complete or partial response (CR or PR) until objective tumor progression. Tumor measurements will be obtained using CT scans of chest, abdomen and pelvis and assessed per RECIST v 1.1. Complete response (CR) is defined as a disappearance of all lesions; partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the baseline sum LD as reference. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for progressive disease, taking as reference the smallest (nadir) sum LD since start of treatment.
 Measure: Duration of Response
 Time: every 8 weeks for 12 months, then every 12 weeks thereafter, estimated 18 months
 Description: Defined as the percentage of complete and partial responses (CR + PR) among all patients. Complete response (CR) is defined as a disappearance of all lesions; partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the baseline sum LD as reference. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for progressive disease, taking as reference the smallest (nadir) sum LD since start of treatment.
 Measure: Objective Response Rate
 Time: every 8 weeks for 12 months, then every 12 weeks thereafter, estimated 18 months
 Description: Adverse events will be graded using CTCAE v4.3. and will be collected until 30 days after the discontinuation of study treatment for each participant. A non-serious adverse event is any untoward medical occurrence. A serious adverse event (SAE) is an event that meets one or more of the following: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage. Specific AE and SAE terms are provided in the Adverse event module.
 Measure: Number of Participants With Serious and Non-serious Adverse Events as a Measure of Safety.
 Time: Every 2 weeks for 8 weeks, then every 8 weeks thereafter, estimated 24 months
2 A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer 
      The goal of this clinical research study is to find the highest tolerable dose of the
      combination of erlotinib and pralatrexate that can be given to patients with advanced cancer.
      The safety of the drug combination will also be studied.
      Pralatrexate is designed to block the body's ability to make folic acid, a protein that may
      help cancer tissue to develop and spread.
      Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells
      to grow. Erlotinib may help slow the growth of tumors.
    
NCT01532011  Advanced Cancers  Solid Tumors  Drug: Erlotinib  Drug: Pralatrexate MeSH: Neoplasms   
HPO: Neoplasm   
For the MTD expansion cohort, patients will be eligible if they meet one of the
             following criteria: I. Have an epidermal growth factor receptor (EGFR)-sensitive
             mutation (as G719C in exon 18, E746-A750 in exon 90, L858R in exon 21) and have been
             previously treated with EGFR inhibitor therapy but have subsequently developed
             resistance, OR II. --- G719C --- 
  Primary Outcomes 
 Description: MTD defined by dose limiting toxicities (DLTs) that occur in the first cycle. DLT defined as any Grade 3 or 4 non-hematologic toxicity as defined in the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0. Grade 4 hematologic toxicity lasting 2 weeks or longer despite supportive care. Grade 4 nausea or vomiting > 5 days despite maximum anti-nausea regimens, and any other Grade 3 non-hematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome; or any severe or life-threatening complication or abnormality not defined in NCI-CTCAE as attributable to therapy.
 Measure: Maximum Tolerated Dose (MTD) of Erlotinib with Pralatrexate
 Time: 8 weeks
  Secondary Outcomes 
 Description: Tumor response defined as one or more of the following: (1) stable disease for more than or equal to 4 months, (2) decrease in measurable tumor (sentinel lesions) by more than or equal to 20% by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, (3) decrease in tumor markers by more than or equal to 25% (for example, a >/= 25% decrease in CA125 for patients with ovarian cancer), or (4) a partial response according to the Choi criteria, i.e. decrease in size by 10% or more, or a decrease in tumor density, as measured in Hounsfield units (HU), by more than or equal to 15% (28).
 Measure: Tumor Response
 Time: 8 weeks
3 A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer 
      The purpose of this study is to test whether the combination of bevacizumab and erlotinib can
      prolong progression free survival as compared with erlotinib alone as first-line treatment in
      patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.
    
NCT02633189  Non-squamous Non-small Cell Lung Cancer  Drug: Erlotinib  Drug: Bevacizumab MeSH: Lung Neoplasms    Carcinoma, Non-Small-Cell Lung   
HPO: Neoplasm of the lung    Non-small cell lung carcinoma   
Inclusion Criteria:
          1. Age ≥18 years
          2. Histological documentation of primary non squamous lung carcinoma
          3. Stage IV or IIIB disease with supraclavicular metastatic nodes (according to TNM 7th
             edition)
          4. Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R
             mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18
             G719S, G719A and G719C, exon 20 S768I and V769L). --- L858R ---  --- L861Q ---  --- G719S ---  --- G719A ---  --- G719C --- 
  Primary Outcomes 
 Description: as determined by investigator
 Measure: progression free survival
 Time: up to 2 years
 Description: as determined by an independent central review board blinded to study treatment
 Measure: progression free survival
 Time: up to 2 years
  Secondary Outcomes 
 Measure: overall survival
 Time: 1 year
 Measure: changes in quality of life scores from baseline
 Time: up to 2 years
 Measure: number of patients with complete and partial responses , investigator assessed
 Time: 6 months
 Measure: number of patients with complete and partial responses , centrally reviewed
 Time: 6 months
 Measure: worst grade toxicity per patient
 Time: up to one year
 Measure: progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)
 Time: 2 years
  Other Outcomes 
 Description: samples taken at baseline, 6 weeks, 6 months, and at progression
 Measure: number and type of EGFR mutations in plasma samples
 Time: up to 2 years
HPO Nodes
Non-small cell lung carcinoma 
Genes 3
TP53  TP53  BAP1   hr>
Neoplasm of the lung 
Genes 61
REST  GPC3  WT1  HPGD  BRAF  PIK3CA  TP53  TRIM28  RB1  TRIP13  SLCO2A1  AKT1  CASP8  KRAS  TSC1  POU6F2  EWSR1  PRKN  LMNA  NAB2  TERT  TSC2  SLC22A18  BRCA2  PPP2R1B  STAT6  STK11  MUC5B  ERBB2  TSC2  MBTPS2  BAP1  TSC2  DICER1  PDGFRB  PERP  EGFR  TSC1  DIS3L2  NOTCH3  KEAP1  DICER1  DICER1  WT1  TSC1  C11ORF95  IRF1  CYP2A6  WRN  RELA  WT1  PTEN  SFTPC  SFTPA2  ERCC6  TRPV3  TP53  H19  TRIM28  FASLG  MAP3K8   hr>
Neoplasm 
Genes 1473
GPC3  LETM1  LZTS1  REST  MPL  ARID1B  RPL18  MGMT  GLI3  BIRC3  ZSWIM6  TRNS2  ETV6  HNF1B  KIT  BRCA1  SUFU  PLAG1  SOX9  TP63  CTSC  RASA1  ATRX  TRIM37  SUFU  BTK  CYP11B1  NOTCH3  EPCAM  PORCN  PIGL  AR  TET2  FH  TGIF1  HMBS  ATRX  TREX1  SMAD4  KRT17  FGFR1  WDPCP  SF3B1  GPR101  KIT  GLI1  SLC25A11  XRCC4  SDHD  PRKCD  RNF43  SDHB  BAP1  EGFR  PIGA  NF1  ASCL1  MPL  RET  C2CD3  GDNF  NR5A1  DICER1  TNFRSF4  CASP10  TERC  FGF8  PSAP  CIB1  SLC22A18  PTCH2  ENPP1  CDKN2C  SLC25A11  GPR101  KIT  AXIN2  TREX1  DYNC2LI1  ERCC4  RPS14  COMP  TINF2  FOXE1  DHCR24  RPS7  TYROBP  HOXD13  ERBB2  BLK  EYA1  ZFPM2  ERCC6  NLRP1  STAC3  ERCC5  NUTM1  MEN1  WT1  BCL10  GNPTAB  KRAS  TP53  KDR  PUF60  TRNF  FCN3  SDHC  KCNH1  MSTO1  EP300  BUB1B  GNA11  KCNE3  DOCK8  SEMA3C  ACD  GLI2  SMPD1  SUFU  NF1  PTCH2  ACAN  DCC  WT1  CTSA  KIF11  BCR  SRGAP1  KIT  PTEN  LEMD3  MLLT10  SCN4A  BRCA2  BMPR1A  NOTCH3  SEC23A  CDKN1C  BARD1  SPIB  RSPO1  MC2R  CALR  ATP6V1B2  NBN  RAD54L  MST1  SUFU  MYCN  TMEM127  SRD5A3  IGF2  CD28  RUNX1  OGG1  HAX1  SDHC  CTNNB1  MST1R  SDHA  IGF2  KCNJ10  IL12RB1  MEN1  RAD51  TFE3  ND5  MMEL1  MVK  APC  FLI1  RNF6  NF1  BRCA2  SUFU  GPC6  NR4A3  TTC37  KIT  NRTN  BLNK  IGH  SPRED1  TXNRD2  IGF2R  FOXP1  BUB1B  SOS1  LRP5  GJB2  DNMT3A  PMS2  PRKN  RET  MSH6  ACVRL1  MPLKIP  ERCC2  AIP  GNAS  TAL1  NNT  RECQL4  PMS1  DLL1  EIF2AK4  STAT6  MNX1  SDHB  KRAS  MEN1  MN1  SH2B3  EFL1  VHL  KLLN  RMRP  RUNX1  SIX3  GDNF  FANCD2  EXT1  CDH23  BRD4  DLEC1  NODAL  CARMIL2  SDHB  MSH2  HMBS  SMAD4  SRP72  NRAS  DOCK8  SPRTN  BRCA1  MAP2K1  KRT14  LETM1  TERT  MAP2K2  HRAS  WHCR  WT1  IDH1  TMEM107  SCN10A  GJB3  SDHD  KRAS  GATA1  RPS20  GJB2  SLX4  USP8  PRKAR1A  CR2  JAK2  HFE  MPL  POT1  BRCA2  GNAI3  SDHB  ALK  OCA2  TP53  GPC4  ACTG2  CTNNB1  HSPG2  AR  FGFR1  STK4  MET  TMC8  MRAP  MSH6  CCBE1  EWSR1  LMO1  EDN3  LEMD3  PGM3  FGFR3  CASP8  RB1CC1  SCN9A  FANCL  TG  SDHD  COX3  IGF2  COL11A2  AGGF1  GPR101  PRKN  PLCB4  SDHD  NF1  GTF2E2  MAP2K1  ESCO2  CDC73  WRAP53  TET2  PDGFRB  RNASEH2A  RAD21  HNF1A  TGFBR2  POLD1  COX2  TNFRSF10B  MINPP1  DNAJC21  FAS  EXT1  SLC26A2  APC  SDHAF2  TINF2  LIG4  POLR1D  WWOX  TMC6  RPS19  ERCC2  SASH1  MC1R  MVD  SEC23B  CYP2A6  GPC3  KIT  HRAS  RAD54L  SDHA  GDNF  NKX2-1  GFI1  ALX3  STAT3  MYH11  DYNC2LI1  FGFR2  TCOF1  PTEN  MAFA  PIK3R1  SLC25A13  HRAS  VHL  COL7A1  GNAS  FGFR2  PIK3CA  GPC4  DICER1  ERCC3  PIK3CA  RAD51C  RB1  RMRP  MLH3  ATM  COL7A1  LIG4  NF1  VAMP7  RPL35A  RB1  SETD2  BCL10  LPP  NRAS  KRAS  ABCA5  ERCC2  PDE6D  KCNQ1OT1  MS4A1  SLC22A18  APC  LIG4  JAK2  FANCD2  GAS1  STAG3  NRAS  PALLD  SLC22A18  RFWD3  PPP2R1B  APC  PTPN11  PTEN  WIPF1  PIK3CA  NOP10  IL7  UROD  TNFRSF1B  TP53  REST  SLC37A4  NHP2  CXCR4  KIT  CYSLTR2  FZD2  ALX4  BMPR1A  SRY  TRNQ  SDHD  PIGL  CCM2  FIBP  FANCI  GJB4  SPINK1  RPL10  NSD2  MAP3K1  RET  CDK4  HSPA9  TET2  GFI1B  MAD2L2  DCC  AP2S1  SMAD7  BRCA2  TRNK  ERCC3  BRCA1  ELANE  SFTPC  PTH1R  COL1A1  FUZ  OFD1  RET  FLT4  PRKAR1A  SBDS  RPL26  SMARCE1  SMARCAD1  MSH2  BCR  GPR35  INTU  FANCA  STAT1  ANTXR2  FGFRL1  TUBB  BRAF  SLX4  CASP10  TERT  RAD21  MTOR  TRIP13  MYD88  DPM1  RSPO1  PTPN11  CTNNB1  AIP  PTEN  VANGL1  CYP2D6  RPS10  GCK  KRT16  DNAJC21  BCL2  AKT1  KRAS  KLF6  NOTCH1  FLNA  MAX  NF2  PALB2  TP53  PSENEN  RNF6  TSC1  HNF1B  TP53  RFWD3  SDHD  PERP  TP53  DIS3L2  B3GALT6  STS  PDGFB  SMARCB1  BRAF  BRIP1  CBFB  BUB1  BLM  INHBA  CALR  NBN  MLH3  TAF1  MLF1  PIK3CA  MSH2  CTLA4  ND6  PALB2  WT1  PTCH1  POLE  ADA  MC1R  FLT4  ATP7A  MLH3  SMO  TRNF  NRAS  LMNA  DLST  TRNL1  MTAP  TP53  ZAP70  SDHB  CHEK2  PALB2  FLT4  CDK4  NBN  MSR1  CC2D2A  TNPO3  ECE1  RPS15A  NAGS  TMEM67  HNF1A  PIK3CA  ATP7A  AKT1  NRAS  SDHAF2  CXCR4  TSC2  NF2  EPHB2  WDPCP  OFD1  BUB1  FLT3  APC  SMARCA4  CDKN2A  RPS29  MCM4  PDGFRA  ESCO2  CTC1  ESR1  SDHB  MSH6  APC  HABP2  GNAQ  KIF1B  SH3GL1  CD70  MPL  IGH  ZIC2  GCM2  VEGFC  HRAS  CTNNB1  KCNH1  LRRC8A  BRAF  FAS  ICOS  NSD1  RNF43  AKT1  BIN1  DLC1  SH2B3  RARA  WNT10A  CARD14  SDHC  EXOC6B  ESCO2  POLR1C  G6PC  MSH6  KRT1  PDX1  TNFRSF13C  ERCC3  EVC  SNAI2  CD79A  BRCA1  RNASEH2B  CCND1  TP53  RPS19  H19  H19  BRCA2  TFAP2A  ARMC5  FASLG  FGFR3  APC  F5  EDN1  MAP3K8  AIP  APC  AKT1  TERC  CCND1  CEL  MYC  TP53  GPC4  ERCC5  HNF1A  POLE  DAXX  NUP214  TRIP13  AKT1  TET2  CDC73  ND1  MUTYH  PIK3R1  TERT  CEBPA  EXT2  OCRL  DIS3L2  ADAR  TGFBR2  BRCA2  MRE11  SOS1  HNF4A  FAH  TMEM127  WT1  AXIN2  TCF4  EDN3  PTPN3  KRAS  SEMA4A  PIK3CA  XPA  MFN2  TINF2  PIK3CA  APPL1  RUNX1  GNPTAB  FGFR3  NRAS  PDCD10  RAG2  PTEN  CTNNB1  SOX2  BMPR1A  HBB  TERT  USP9X  NFKB1  FANCC  PRF1  WRN  SRY  SRSF2  PMS2  RHBDF2  PHOX2B  RPS17  PAX3  RECQL4  KIF1B  SQSTM1  RB1  EXT1  XPC  CYLD  TOP2A  MYD88  CDKN1B  TET2  GJB2  PTEN  UBE2T  RTEL1  PTCH1  KLHDC8B  GATA1  POLH  JAK2  RHOH  FLCN  DCLRE1C  MTMR14  GTF2H5  PTEN  SBDS  TBC1D24  PAX7  AR  TP53  ASPSCR1  MTM1  RECQL4  ERCC2  TGFBR2  ERCC4  JAK2  SF3B1  CDKN2B  XPC  GATA4  KIT  POU2AF1  BRCA2  GREM1  CDON  NTHL1  DICER1  GINS1  ATM  RAD51D  SHOX  EXT1  RASGRP1  WT1  GATA2  NF2  ERCC4  TUBB  MBTPS2  DHCR7  MYLK  KCNN3  TCTN3  TMEM216  TMEM231  KRT1  CTNNB1  MPL  PDGFRB  FANCG  RPGRIP1L  KEAP1  DICER1  WT1  BAP1  FOXI1  ERCC4  CDKN2A  FGFR3  KDSR  CBL  HRAS  BMPR1A  DISP1  RELA  MAP3K1  PARN  BCR  ENG  COL7A1  LMOD1  KRAS  PAX6  SNAI2  GLI3  FANCF  FOXO1  RPL15  TBX18  TRPV3  PIK3CA  NRAS  CDH1  GNAS  SMARCB1  KLF11  ADA2  EDN3  POU6F2  CDH1  GNAS  IL1B  SMAD4  H19-ICR  SDHB  STK11  NF2  TRIM28  SEC23A  SLCO2A1  BRCA2  BRAF  DNMT3A  MDM2  BMP2  BRCA2  DHH  NRAS  POU6F2  CTBP1  PTCH2  FLCN  CALR  BAP1  LIG4  HRAS  REST  BRAF  SAMD9  NDP  TYR  KRT17  MUC5B  PRSS1  MEN1  NPM1  ITK  MSH2  CYLD  TAL2  SRP54  IFIH1  HMMR  TCTN3  ND5  JAK2  FAM20C  RET  NEK9  DMRT3  KRAS  MINPP1  SH3KBP1  THPO  FAH  KRT5  JAK2  PHKG2  TSC1  TNFRSF13C  MEN1  FH  RPL31  FANCG  PIK3CA  IL2RG  DNAJC21  VANGL2  MYO1H  ALX1  CDKN2A  AIP  H19  NRAS  TWIST1  PTEN  TRNK  TRPS1  RPS26  MAPRE2  RPS27  TCF3  KRT17  ERCC6  DHH  MMP1  FGFR1  SEMA3D  PTCH1  ABL1  CDKN2A  SKI  APC  WWOX  ZSWIM6  NF2  WNT10A  KRAS  GPC3  REST  GJB6  HRAS  VHL  CTNNB1  TGFBR1  IL6  TDGF1  RPL11  IL1RN  BRCA1  MGAT2  POT1  ASCC1  XPA  TBX2  FLCN  HFE  NTHL1  SMARCB1  DVL3  TRNH  IDH1  FANCA  LAMB3  CD79B  RAD51C  PRDM16  PHOX2B  GNAQ  CCL2  PDGFRA  CREB1  SRP54  PIEZO2  TRNL1  GBA  GNAS  WNT5A  PIK3CA  STS  FANCB  KRAS  MAGT1  RAD51  IDH1  TNFRSF13B  TREM2  GABRD  BCL10  SKIV2L  POLD1  KRIT1  KRAS  ARSA  SMAD4  RAD51  TP53  DIS3L2  KIAA0753  PRLR  CD96  LZTR1  WRN  GATA2  EDNRB  MUTYH  ATM  CHIC2  TP53  CYLD  PAX4  SLC26A4  RTEL1  VHL  NEK1  TRNS1  GCM2  TYR  ATP7B  CTHRC1  BRAF  ASXL1  OFD1  MLH1  CDKN1A  PHOX2B  XRCC2  CD19  RB1  FOXC2  TRIM28  EWSR1  TERT  GNA11  F13B  CDKN2A  KARS1  BCL10  TP53  WT1  CDKN2A  FDPS  KIT  COX1  COL14A1  VHL  WT1  TERT  SMAD4  STAR  NUMA1  RPL5  PDGFB  PCGF2  CFTR  KCNQ1OT1  KIT  GJA1  GNAQ  CD27  FANCC  IDH2  EVC2  BRCA2  TCF4  KRAS  PIK3CA  CDC73  ACVR1  BRIP1  TRNW  PRCC  GCGR  CDKN1B  STK11  SCN11A  TGFBR2  AXIN2  ERBB2  RPL35  APC  TSC2  IL12A  SSX2  TET2  KIF1B  DICER1  TRNP  BTK  CCDC22  PDGFRA  ALX3  ADAMTS3  CD81  RET  DKC1  GLI3  FGF3  SMAD4  STK11  ERCC6  WT1  ELANE  C11ORF95  SAMD9L  SLC45A2  NQO2  PTPN11  ATR  PDGFRL  TNFSF12  BRCA2  ADA  BUB1B  FASLG  GDF5  KRAS  CPLANE1  CREBBP  CDC73  CLCNKB  GATA2  CTRC  SDHA  ACTB  APC  BMPER  SPINK1  APC2  MC1R  FOXI1  DYNC2H1  KIT  PPM1D  SDHC  NSD1  SDHC  DDX41  ANTXR1  CASP8  F13A1  SUFU  INS  NUP214  ANTXR2  KIF7  NFKB2  ABCC8  TARS1  ERCC3  TCIRG1  ND4  ERCC2  GNAS  TERT  WASHC5  SLC49A4  RERE  CALR  MSH3  PHOX2B  SLC25A13  BMPR1B  CYLD  SIX6  ASCL1  IDH2  FAN1  CHRNG  CBL  NEUROD1  MSH3  THPO  VANGL1  CDKN2B  TAF15  PTCH2  HMGA2  MSH6  CHEK2  FN1  GATA2  IRF1  KRAS  BMPR1A  NPM1  ERCC3  CDH1  ALK  DNM2  ERBB3  PTPN11  DLST  MUTYH  PARN  GFI1  NBN  FGFR3  CHEK2  EP300  RNF113A  TNFSF15  TEK  TERF2IP  ICOS  COL18A1  TNFSF12  BRAF  CHEK2  IFNG  TMC6  USB1  KDM6B  GJC2  SLC26A2  MDH2  TP53  ENG  MLH1  KRT6B  MNX1  PDGFB  TRNH  POLE  CASP10  HPGD  TET2  RB1  PHOX2B  JAG1  GNB1  ACD  TNFRSF13B  MYC  BRAF  TSC1  SAMD9L  BCL10  H19  POT1  USP8  IGF2  OFD1  CYP11B2  KCNQ1  CDH1  LMX1B  TET2  ANTXR1  JAK2  SMARCB1  ELMO2  PTCH1  SIX1  L2HGDH  WRAP53  BUB3  AXIN1  RET  KCNJ11  ABL1  FANCE  RAD54B  FANCM  TSC2  MAX  IGHM  TSC1  HACE1  CASR  RNF139  MITF  RAF1  WT1  TCTN3  POLH  LIG4  TP53  KRT10  AAGAB  SRY  RAD50  TNFRSF1B  TRNQ  DNASE1L3  FAM149B1  KRT9  VHL  FLCN  TBXT  SLC37A4  DKC1  PNP  DDB2  SETBP1  ECM1  MSH2  CR2  COL2A1  COL7A1  MLH1  FH  SFTPA2  PIK3CA  FOXH1  MET  HNF4A  H19  KAT6B  GPR143  PHB  PMS1  ATP7A  FAT4  TJP2  TFAP2A  GDF2  AHCY  TSC2  CD19  TRNS1  BDNF  TRIP13  AKT1  FGFR2  RAG1  BRCA1  SDHC  MLH1  XRCC3  NSD2  LMNA  SDHC  TERC  EXT2  PIK3CA  MSH3  SDHD  SRC  CHEK2  C1S  ABCA5  HBB  RYR1  FGFR2  CDC73  KIT  FANCE  RET  LYST  KCNJ10  BCHE  HDAC4  INPP5E  CRKL  PHOX2B  BAP1  CPLX1  PDGFRB  ARL6IP6  RNASEL  SETBP1  CTLA4  PALB2  DCLRE1C  NSUN2  XIAP  TRNS2  BMPR1A  IL7R  BCL6  COL4A5  PIK3CA  NOD2  PRKAR1A  NELFA  IL2RG  MYH8  RHBDF2  IGLL1  PIK3CA  SERPINA1  FOXE1  ARHGAP26  TCF4  MITF  ABCB11  ERBB2  GNA14  SLC26A2  NSD1  SH2B3  STK11  PTCH1  GDNF  RPL27  DHCR7  WAS  CIB1  SHH  CACNA1S  LIN28B  SF3B1  ATM  PRKCD  RPS24  LAMA3  ATRX  CASP8  AKT1  OPCML  HFE  SH2D1A  ING1  CCND1  SLC12A3  HABP2  H19  LAMC2  RAD51C  NAB2  NRAS  MAPK1  CPLANE1  CYP26C1  CDKN1B  CHD7  IGH  MYF6  BLM  ASXL1  FH  NEK1  HLA-DRB1  SLC26A4  RPS14  SHOX  RNASEH2C  SMARCD2  GATA2  CDH23  WT1  EPCAM  NR0B1  KLLN  DVL1  SEC23B  GPC3  SLC17A9  BRCA1  SRP54  DKC1  RECQL4  CD28  PTPN11  HRAS  NBEAL2  BARD1  MLH1  DDB2  PMS2  IRF1  ABCC6  EXT2  ASXL1  TSR2  PTEN  MALT1  PTEN  BCR  PALB2  BRIP1  SSX1  PHKA2  FGFR2  SDHB  FERMT1  KCNAB2  FLT3  PMVK  MSTO1  CEP57  MMP1  PICALM  IRF5  TP53  PTPRJ  RNR1  WWOX  PLCD1  RPS28  FGFR3  COL2A1  IKBKG  TERT  RASA1  SAMHD1  PHF21A   hr>